# Epinastine + Pseudoephedrine SR (Slow Release) Versus Epinastine Alone in Patients With Perennial Allergic Rhinitis

> **NCT02182518** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 101 (actual)

## Conditions studied

- Rhinitis, Allergic, Perennial

## Interventions

- **DRUG:** Epinastine
- **DRUG:** Pseudoephedrine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02182518
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-05
- **Primary completion:** 2001-07
- **Final completion:** —
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2014-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02182518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02182518, "Epinastine + Pseudoephedrine SR (Slow Release) Versus Epinastine Alone in Patients With Perennial Allergic Rhinitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02182518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*